How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1371-1377

  Bradford, W David ^a   Kleit, Andrew N ^b   Nietert, Paul J ^c   Steyer, Terrence ^c   McIlwain, Thomas ^c   Ornstein, Steven ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Department of Biostatistics Bioinformatics and Epidemiology ^*

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; PYRAZOLE DERIVATIVE; ROFECOXIB; SULFONAMIDE; SULFONE;

ADVERTIZING; ARTICLE; CLINICAL PRACTICE; DOCTOR PATIENT RELATION; DRUG INDUSTRY; DRUG UTILIZATION; ECONOMICS; HUMAN; OSTEOARTHRITIS; PATIENT SATISFACTION; PRIMARY HEALTH CARE; STATISTICS; TELEVISION; UNITED STATES;

ADVERTISING; ADVERTISING AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DRUG INDUSTRY; DRUG UTILIZATION; HUMANS; LACTONES; OSTEOARTHRITIS; PATIENT SATISFACTION; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; PRIMARY HEALTH CARE; PYRAZOLES; SULFONAMIDES; SULFONES; TELEVISION; UNITED STATES;

EID: 33749359193     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1371     Document Type: Article

References (30)

1. T. Nordenberg, "TV Drug Ads That Make Sense," Consumers' Research Magazine 81, no. 3 (1998): 28-31;
2. and S. Elliot, "With or Without Vioxx, Drug Ads Proliferate," New York Times, 6 December 2004.
3. M. Schumann, "Top 100 Megabrands: Chevrolet Leads the Race along Megabrand Road, but Marketers Hit 2001 Potholes," Advertising Age 72, no. 1 (2001): 1.
4. G. Kolata, "A Widely Used Arthritis Drug Is Withdrawn," New York Times, 1 October 2004.
5. E.J. Topol, "Failing the Public Health - Rofecoxib, Merck, and the FDA," New England Journal of Medicine 351, no. 17 (2004): 1707-1709;
6. and D. Mukherjee, S.E. Nissen, and E.J. Topol, "Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 286, no. 8 (2001): 954-959.
7. A. Masson and P.H. Rubin, "Matching Prescription Drugs and Consumers: The Benefits of Direct Advertising," New England Journal of Medicine 313, no. 8 (1985): 513-515;
8. and A. Keith, "Regulating Information about Aspirin and the Prevention of Heart Attack," American Economic Review 85, no. 2 (1995): 96-99.
9. M.A. Hurwitz and R.E. Caves, "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals," Journal of Law and Economics 31, no. 2 (1988): 299-320;
10. C. King, "Marketing, Product Differentiation, and Competition in the Pharmaceutical Industry" (Working Paper, Massachusetts Institute of Technology, Department of Economics, 1996);
11. and J.A. Rizzo, "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Hypertensive Drugs," Journal of Law and Economics 42, no. 1 (1999): 89-116.
12. W.M. Zachry III and D.B. Ginsburg, "Patient Autonomy and the Regulation of Direct-to-Consumer Advertising," Clinical Therapeutics 23, no. 12 (2001): 2024-2037.
13. J.E. Calfee, C. Winston, and R. Stempski, "Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs," Journal of Law and Economics 45, no. 2, part 2 (2002): 673-690.
14. F.F. Gonul, F. Carter, and J. Wind, "What Kind of Patients and Physicians Value Direct-to-Consumer Advertising of Prescription Drugs?" Health Care Management Science 3, no. 3 (2000): 215-226;
15. N. Sumpradit, S.W. Fors, and L. McCormick, "Consumers' Attitudes and Behavior toward Prescription Drug Advertising," American Journal of Health Behavior 26, no. 1 (2002): 68-75;
16. W.M. Zachry III, J.E. Dalen, and T.R. Jackson, "Clinicians' Responses to Direct-to-Consumer Advertising of Prescription Medications," Archives of Internal Medicine 163, no. 15 (2003): 1808-1812;
17. and J.S. Weissman et al., "Consumers' Reports on the Health Effects of Direct-to-Consumer Drug Advertising," Health Affairs 22 (2003): w82-w95 (published online 26 February 2003; 10.1377/hlthaff.w3.82).
18. We explored alternative measures of DTC advertising. In one, we included current-month and six-month cumulative lagged ad measures. The six-month lagged measures were not significant, and the current-month effects were unchanged. In a second, we included current-month and one- and two-month lagged measures. The parameters on the current-month DTC ads were largely unchanged, but the significance level on all measures was lower as a result of collinearity between the three monthly measures included in the same model.
19. Mukherjee et al., "Risk of Cardiovascular Events."
20. The regression results are available as online exhibits. See Online Supplemental Exhibit 1 at http://content.healthaffairs.org/cgi/content/full/25/ 4/1371/DC1.
21. See Online Supplemental Exhibit 2, ibid.
22. See Online Supplemental Exhibit 3, ibid.
23. See Notes 13 and 14.
24. Mukherjee et al., "Risk of Cardiovascular Events." This article had a significant effect in models where we estimated the DTC effect nonlinearly, but it had an insignificant effect in the linear models we present here. Since this was not a major focus of the paper, we presented the more straightforward linear models here.
25. Topol, "Failing the Public Health."
26. Keith, "Regulating Information";
27. Masson and Rubin, "Matching Prescription Drugs";
28. P.H. Rubin, "Economics of Prescription Drug Advertising," Journal of Pharmaceutical Finance, Economics, and Policy 3, no. 4 (1991): 29-39;
29. and P.H. Rubin and J.L. Schrag, "Mitigating Agency Problems by Advertising, with Special Reference to Managed Health Care," Southern Economic Journal 66, no. 1 (1999): 39-60.
30. U.S. Government Accountability Office, Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations (Washington: GAO, 2002).